Key result
Cisplatin-induced nephrotoxicity may occur at substantially smaller dosages than the standard 60 mg/m2 dose in the TPF regimen, highlighting the need for individualized dose adjustments.
Why the study?
Nephrotoxicity is a well-known side effect of cisplatin, prompting an evaluation of the relationship between administered cisplatin dosage causing nephrotoxicity and patient background factors in the TPF regimen.
What dose of cisplatin in the TPF regimen is associated with nephrotoxicity in cancer patients?
Observational
What dose of cisplatin in the TPF regimen is associated with nephrotoxicity in cancer patients?
Cisplatin-induced nephrotoxicity in the TPF regimen can occur at doses substantially lower than the standard 60 mg/m2, highlighting the need for individualized dose adjustments based on patient background factors.
May warrant renal monitoring at lower cisplatin doses in TPF; leaves open optimal individualized adjustments pending prospective trials.
Nephrotoxicity is a well-known side effect of cisplatin for cancer treatment. Various regimens have been developed to treat cancer based on the type and severity of the tumor. We focus on the docetaxel, cisplatin, and 5-fluorouracil regimen, which is called the TPF regimen, where the standard dose of cisplatin is 60 mg/m2. The aim of this study is to examine the relationship of the dosage of cisplatin that causes nephrotoxicity and back ground factors of patients using information about the dose of cisplatin actually administered to patients. It is shown that nephrotoxicity may be caused by a substantially smaller dosage than the standard dose of cisplatin in the TPF regimen, indicating the need for dose adjustment, taking into account the patient's background factors in the treatment of a cancer.
No takes yet. Share an insight, caveat, or question.
Higuchi et al. (2019) conducted an observational in Cancer. Cisplatin dosage was evaluated on Nephrotoxicity. Cisplatin-induced nephrotoxicity may occur at substantially smaller dosages than the standard 60 mg/m2 dose in the TPF regimen, highlighting the need for individualized dose adjustments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: